Windtree Therapeutics Stock Today
| WINT Stock | USD 0.14 0.01 6.67% |
PerformanceVery Weak
| Odds Of DistressVery High
|
Windtree Therapeutics is selling for under 0.14 as of the 17th of February 2025; that is 6.67 percent decrease since the beginning of the trading day. The stock's last reported lowest price was 0.13. Windtree Therapeutics has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 28th of February 2023 and ending today, the 17th of February 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 8th of August 1995 | Category Healthcare | Classification Health Care |
Windtree Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of acute cardiovascular and secondarily in acute pulmonary diseases. Windtree Therapeutics, Inc. is a subsidiary of Lees Pharmaceutical Holdings Limited. The company has 8.75 M outstanding shares of which 174.05 K shares are at this time shorted by private and institutional investors with about 0.06 trading days to cover. More on Windtree Therapeutics
Moving together with Windtree Stock
Moving against Windtree Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Windtree Stock Highlights
| President CEO, Director | Craig Fraser | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Old Name | West International AB (publ) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsWindtree Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Windtree Therapeutics' financial leverage. It provides some insight into what part of Windtree Therapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Windtree Therapeutics (WINT) is traded on NASDAQ Exchange in USA. It is located in 2600 Kelly Road, Warrington, PA, United States, 18976-3622 and employs 13 people. Windtree Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 4.92 M. Windtree Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 8.75 M outstanding shares of which 174.05 K shares are at this time shorted by private and institutional investors with about 0.06 trading days to cover.
Windtree Therapeutics currently holds about 11.38 M in cash with (13.44 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.37, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Windtree Therapeutics Probability Of Bankruptcy
Ownership AllocationRoughly 99.14 (%) of Windtree Therapeutics outstanding shares are held by general public with 0.27 % owned by insiders and only 0.59 percent by institutional investors.
Check Windtree Ownership Details
Windtree Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Armistice Capital, Llc | 2024-09-30 | 157 K | |
| Morgan Stanley - Brokerage Accounts | 2024-09-30 | 3.7 K | |
| Tower Research Capital Llc | 2024-09-30 | 1.9 K | |
| Ubs Group Ag | 2024-09-30 | 387 | |
| Bank Of America Corp | 2024-09-30 | 4.0 | |
| Royal Bank Of Canada | 2024-09-30 | 2.0 | |
| Activest Wealth Management | 2024-12-31 | 2.0 | |
| Ifp Advisors, Llc | 2024-12-31 | 0.0 |
Windtree Therapeutics Historical Income Statement
Windtree Stock Against Markets
Windtree Therapeutics Corporate Management
| George Cox | Vice Operations | Profile | |
| Pratap Paruchuru | Executive Development | Profile | |
| Tracy Rarick | Head Management | Profile | |
| Diane Esq | Sr Counsel | Profile |
Already Invested in Windtree Therapeutics?
The danger of trading Windtree Therapeutics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Windtree Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Windtree Therapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Windtree Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Additional Tools for Windtree Stock Analysis
When running Windtree Therapeutics' price analysis, check to measure Windtree Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Windtree Therapeutics is operating at the current time. Most of Windtree Therapeutics' value examination focuses on studying past and present price action to predict the probability of Windtree Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Windtree Therapeutics' price. Additionally, you may evaluate how the addition of Windtree Therapeutics to your portfolios can decrease your overall portfolio volatility.